Generic Injectables Market: Global Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2017-2021 and Forecast 2022 to 2028

$ PRICE - $ 3,000.00$ 8,900.00

Global Generic Injectables Market By Product Type (Monoclonal Antibodies, Cytokines, Insulin, Peptide Hormones, Blood Factors, Immunoglobulins, Peptide Antibiotics, Vaccines, and Others), Indication (Diabetes, Cancer, Cardiovascular Diseases, Musculoskeletal, CNS, Infections, and Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Drug Stores, and Online Prescription Stores), and Geography

 

$ PRICE - $ 3,000.00$ 8,900.00
Clear selection
Clear
$ PRICE - $ 3,000.00$ 8,900.00
FacebookTwitterLinkedinEmail

Report

Description

The Generic Injectables market is valued at USD 20.0 billion in 2021 and is poised to grow at a significant CAGR of 11.0% over 2022–2028. Generic injectables are bioequivalent to their branded counterparts; they are as safe and effective as innovator compounds. Only after the patent on the branded drug has expired can these medications be created for commercial use. Generic injectables have low R&D costs because the drug molecules are equivalent in branded and generic formulations. Drugmakers can sell generic injectables at low prices because of the minimal upfront R&D costs. According to the USFDA, a single generic competitor can result in price reductions of 30%, whereas five generic competitors can result in price reductions of 85%. Furthermore, generic drugs are approved faster than branded medicines. According to the US Food and Drug Administration (USFDA), 107 first-generation generic pharmaceuticals and 110 complicated generic drugs were approved in 2019, accounting for 11% of all generic drug product approvals. One thousand fourteen generic medicine applications were granted or tentatively approved by the generic drug program in 2019. Furthermore, the development of a new chemical entity takes roughly a decade on average, whereas generic injectables are developed in a fraction of that time. As a result, one of the primary drivers encouraging new companies to enter the market and driving the generic injectables market is the lower cost associated with generic injectables. Manufacturers in the generic injectables market are preparing for the future by keeping adequate supply chains to avoid any COVID-19-like vulnerabilities. Drug companies such as Zydus Cadila have been seen lowering the price of Remdac, the generic version of Remdesivir. Companies are utilizing government programs and financing schemes given by the BFSI industry to streamline their operations in response to turbulent market conditions. Furthermore, branded injectables’ patents are set to expire in the coming years in several countries, presenting a lucrative opportunity for generic injectables manufacturers. Generational injectables businesses target regulated markets and explore other markets to generate funds and build steady revenue streams.

Recent Market Developments:

In January 2022, Hikma Pharmaceuticals launched Hikma 503B, a new outsourced sterile compounding business. The unit would focus on providing high-quality, ready-to-administer injectables and customized medications for the US market.

In April 2022, Hospira, Inc., the world leader in generic injectable pharmaceuticals, acquired the generic injectable pharmaceuticals business of Orchid Chemicals & Pharmaceuticals Ltd., a leading Indian pharmaceuticals company, for approximately $400 Billion.

Generic Injectables Market

MARKET SUMMARY
-
11.0%
  • Study Period– 2022 – 2028
  • Base Year– 2021
  • CAGR– 11.0%
  • Largest Market– North-America
  • Fastest Growing Market– Asia-Pacific

Generic Injectables Market

  • The global generic injectables market report gives comprehensive outlook on generic injectables across the globe with special emphasis on key regions such as North America, Europe, Asia Pacific, Latin America, and Middle East and Africa.
  • The report on global generic injectables market gives historical, current, and future market sizes ( Bn) based on product type, indication, distribution channel, and geography.
  • Key stakeholders of the global Generic Injectables market report include suppliers, manufacturers, marketers, and policy makers engaged in global generic injectables products.
Key Players
  • Novartis
  • AbbVie Inc.
  • Amgen, Inc.
  • AstraZeneca Plc
  • Baxter International Inc.
Generic Injectables Market

Dynamics

As medicine shortages worsen, governments in several countries are promoting the production of generic injectables, which do not have patents. The increasing aging population and the rise in chronic disease cases are two further factors contributing to the growth of generic injectables. Since generic injectables are bioequivalent, generic medications have shorter R&D cycles than their branded counterparts, and these benefits producers by reducing time and contributing to expanding the generic injectable market. The expiration of branded injectable patents and a decrease in the frequency of new launches are two reasons that have aided the expansion of the generic injectable industry. On the other hand, the production of generic injectables is relatively complex. In many underdeveloped nations, the absence of competent labor can be a stumbling block for the generic injectable industry.


North-America Got Significant Share

Generic Injectables Market

The generic injectables market in North America is likely to hold the highest revenue share in 2022, and, in the following years, it is predicted to increase rapidly. Governments in several nations are encouraging the production of generic injectables due to their benefits. Other factors driving the market's growth include increased drug shortages, particularly in the United States, the patent expiration of several blockbuster drugs, an aging population, and the increased prevalence of chronic and lifestyle diseases. Asia-Pacific offers abundant growth potential for the global generic injectables market throughout the projection period. High need for injectable antibiotics, owing to the high frequency of infectious diseases including diarrhea, typhoid, malaria, and cholera; rising cancer prevalence; increased demand for low-cost pharmaceuticals; and a substantial market presence by prominent companies are expected to drive the market growth in Asia-Pacific.

Latin America
Latin-America
North-America
North-America
Europe
Europe
Asia Pacific
Asia-Pacific
Middle East
Middle East

Key

Features of the Report

  • The generic injectables market report provides granular level information about the market size, regional market share, historic market (2017-2021), and forecast (2022-2028)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments, and start-up details that are actively working in the market
  • The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario
Generic Injectables Market Segmentation


Location

GEOGRAPHY

Frequently Asked Questions

2021 is the base year and 2028 is the forecast year.

The report covers the five regions and 15+ countries market data: North America (United States, Canada), Europe (Germany, France, Italy, Spain, and United Kingdom (UK), Asia Pacific (China, India, Japan, Australia & New Zealand), Latin America (Brazil, Mexico, Argentina) and Middle East and Africa (Saudi Arabia, United Arab Emirates, South Africa).

In our report, we provide 12-15 market players’ information into the report. However, based on the client’s request we will provide additional country and regional market players information as well.


Report

Table Of Content

Table of Content

  1. Executive Summary
  2. Global Generic Injectables Market Introduction
    • Global Generic Injectables Market – Taxonomy
    • Global Generic Injectables Market –Definitions
      • By MoleculeType
      • By Drug Type
      • By Indication
      • By Route of Administration
      • By Manufacturing Type
      • By Distribution Channel
      • By Presentation Type
      • By End User
  1. Global Generic Injectables Market Dynamics
    • Drivers
    • Restraints
    • Opportunities/Unmet Needs of the Market
    • Trends
    • Global Generic Injectables Market Dynamic Factors – Impact Analysis
    • Global Generic Injectables Market – Competition Landscape
  2. Global Generic Injectables Market Analysis, 2013 – 2018 and Forecast, 2019 – 2023
    • Market Analysis, 2013 – 2018 and Forecast, 2019 – 2023 (Revenue, USD Mn)
    • Year-over-Year (Y-o-Y) Growth Analysis (%)
    • Market Opportunity Analysis
  3. Global Generic Injectables Market, By Molecule Type, 2013 – 2018 and Forecast, 2019 – 2023 (Revenue, USD Mn)
    • Large Molecule
      • Market Analysis, 2013 – 2018 and Forecast, 2019 – 2023 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Small Molecule
      • Market Analysis, 2013 – 2018 and Forecast, 2019 – 2023 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
  1. Global Generic Injectables Market, By Drug Type, 2013 – 2018 and Forecast, 2019 – 2023 (Revenue, USD Mn)
    • Monoclonal Antibodies
      • Market Analysis, 2013 – 2018 and Forecast, 2019 – 2023 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Peptide harmones
      • Market Analysis, 2013 – 2018 and Forecast, 2019 – 2023 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Imunoglobulin
      • Market Analysis, 2013 – 2018 and Forecast, 2019 – 2023 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Cytokines
      • Market Analysis, 2013 – 2018 and Forecast, 2019 – 2023 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Blood Factors
      • Market Analysis, 2013 – 2018 and Forecast, 2019 – 2023 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Peptide harmones
      • Market Analysis, 2013 – 2018 and Forecast, 2019 – 2023 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Insulin
      • Market Analysis, 2013 – 2018 and Forecast, 2019 – 2023 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Vaccines
      • Market Analysis, 2013 – 2018 and Forecast, 2019 – 2023 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Others
      • Market Analysis, 2013 – 2018 and Forecast, 2019 – 2023 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
  1. Global Generic Injectables Market, By Indication, 2013 – 2018 and Forecast, 2019 – 2023 (Revenue, USD Mn)
    • Cancer
      • Market Analysis, 2013 – 2018 and Forecast, 2019 – 2023 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Diabetes
      • Market Analysis, 2013 – 2018 and Forecast, 2019 – 2023 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Cardiovascular Diseases
      • Market Analysis, 2013 – 2018 and Forecast, 2019 – 2023 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Musculoskeletal
      • Market Analysis, 2013 – 2018 and Forecast, 2019 – 2023 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • CNS
      • Market Analysis, 2013 – 2018 and Forecast, 2019 – 2023 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Infections
      • Market Analysis, 2013 – 2018 and Forecast, 2019 – 2023 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Opthalmic
      • Market Analysis, 2013 – 2018 and Forecast, 2019 – 2023 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Infections
      • Market Analysis, 2013 – 2018 and Forecast, 2019 – 2023 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Others
      • Market Analysis, 2013 – 2018 and Forecast, 2019 – 2023 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
  1. Global Generic Injectables Market, By Route of Administration, 2013 – 2018 and Forecast, 2019 – 2023 (Revenue, USD Mn)
    • Intravenous (IV)
      • Market Analysis, 2013 – 2018 and Forecast, 2019 – 2023 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Intramuscular (IM)
      • Market Analysis, 2013 – 2018 and Forecast, 2019 – 2023 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Subcutaneous (SC)
      • Market Analysis, 2013 – 2018 and Forecast, 2019 – 2023 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Others
      • Market Analysis, 2013 – 2018 and Forecast, 2019 – 2023 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
  1. Global Generic Injectables Market, By Manufacturing Type, 2013 – 2018 and Forecast, 2019 – 2023 (Revenue, USD Mn)
    • In-House
      • Market Analysis, 2013 – 2018 and Forecast, 2019 – 2023 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Outsource
      • Market Analysis, 2013 – 2018 and Forecast, 2019 – 2023 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
  1. Global Generic Injectables Market, By Distribution Channel, 2013 – 2018 and Forecast, 2019 – 2023 (Revenue, USD Mn)
    • Hospital Pharmacies
      • Market Analysis, 2013 – 2018 and Forecast, 2019 – 2023 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Retail Pharmacies
      • Market Analysis, 2013 – 2018 and Forecast, 2019 – 2023 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Online Pharmacies
      • Market Analysis, 2013 – 2018 and Forecast, 2019 – 2023 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
  1. Global Generic Injectables Market, By Presentation Type, 2013 – 2018 and Forecast, 2019 – 2023 (Revenue, USD Mn)
    • Ampules
      • Market Analysis, 2013 – 2018 and Forecast, 2019 – 2023 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Vials
      • Market Analysis, 2013 – 2018 and Forecast, 2019 – 2023 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Prefilled Syringes
      • Market Analysis, 2013 – 2018 and Forecast, 2019 – 2023 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Lyophilized Products
      • Market Analysis, 2013 – 2018 and Forecast, 2019 – 2023 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Dry Powder Injectables
      • Market Analysis, 2013 – 2018 and Forecast, 2019 – 2023 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Pen Injections
      • Market Analysis, 2013 – 2018 and Forecast, 2019 – 2023 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
  1. Global Generic Injectables Market, By End User, 2013 – 2018 and Forecast, 2019 – 2023 (Revenue, USD Mn)
    • Human
      • Market Analysis, 2013 – 2018 and Forecast, 2019 – 2023 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Veterinary
      • Market Analysis, 2013 – 2018 and Forecast, 2019 – 2023 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
  1. Global Generic Injectables Market Forecast, By Region, 2013 – 2018 and Forecast, 2019 – 2023 (Revenue, USD Mn)
    • North America
      • Market Analysis, 2013 – 2018 and Forecast, 2019 – 2023 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Europe
      • Market Analysis, 2013 – 2018 and Forecast, 2019 – 2023 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Asia-Pacific
      • Market Analysis, 2013 – 2018 and Forecast, 2019 – 2023 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Latin America
      • Market Analysis, 2013 – 2018 and Forecast, 2019 – 2023 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Middle East and Africa
      • Market Analysis, 2013 – 2018 and Forecast, 2019 – 2023 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Global Generic Injectables Market – Opportunity Analysis Index, By Molecule Type, Drug Type, By Indication, By Route of Administration, Manufacturing Type, By Distribution Channel, By Presentation Type, By End User, and Region, 2019 – 2023
  2. North America Generic Injectables Market Analysis, 2013 – 2018 and Forecast, 2019 – 2023 (Revenue, USD Mn)
    • Molecule Type Analysis 2013 – 2018 and Forecast 2019 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
      • Large Molecule
      • Small Molecule
    • Drug Type Analysis 2013 – 2018 and Forecast 2019 – 2023 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
      • Monoclonal Antibodies
      • Peptide Hormones
      • Immunoglobulin
      • Cytokines
      • Blood Factors
      • Peptide Antibiotics
      • Insulin
      • Vaccines
      • Others
    • By Indication Analysis 2013 – 2018 and Forecast 2019 – 2023 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
      • Cancer
      • Diabetes
      • Cardiovascular Diseases
      • Musculoskeletal
      • CNS
      • Infections
      • Ophthalmic
      • Others
    • By Route of Administration Analysis 2013 – 2018 and Forecast 2019 – 2023 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
      • Intravenous (IV)
      • Intramuscular (IM)
      • Subcutaneous (SC)
      • Others
    • By Manufacturing Type Analysis 2013 – 2018 and Forecast 2019 – 2023 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
      • In-House
      • Outsource
    • By Distribution Channel Analysis 2013 – 2018 and Forecast 2019 – 2023 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
    • By Presentation Type Analysis 2013 – 2018 and Forecast 2019 – 2023 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
      • Ampules
      • Vials
      • Prefilled Syringes
      • Lyophilized Products
      • Dry Powder Injectable
      • Pen Injectors
    • By End User Analysis 2013 – 2018 and Forecast 2019 – 2023 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
      • Human
      • Veterinary
    • Country Analysis 2013 – 2018 and Forecast 2019 – 2023 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
      • US.
      • Canada
    • North America Generic Injectables Market – Opportunity Analysis Index, By Molecule Type, Drug Type, By Indication, By Route of Administration, Manufacturing Type, By Distribution Channel, By Presentation Type, By End User, and Country, 2019 – 2023
    • North America Generic Injectables Market Dynamics – Trends
  3. Europe Generic Injectables Market Analysis, 2013 – 2018 and Forecast, 2019 – 2023 (Revenue, USD Mn)
    • Molecule Type Analysis 2013 – 2018 and Forecast 2019 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
      • Large Molecule
      • Small Molecule
    • Drug Type Analysis 2013 – 2018 and Forecast 2019 – 2023 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
      • Monoclonal Antibodies
      • Peptide Hormones
      • Immunoglobulin
      • Cytokines
      • Blood Factors
      • Peptide Antibiotics
      • Insulin
      • Vaccines
      • Others
    • By Indication Analysis 2013 – 2018 and Forecast 2019 – 2023 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
      • Cancer
      • Diabetes
      • Cardiovascular Diseases
      • Musculoskeletal
      • CNS
      • Infections
      • Ophthalmic
      • Others
    • By Route of Administration Analysis 2013 – 2018 and Forecast 2019 – 2023 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
      • Intravenous (IV)
      • Intramuscular (IM)
      • Subcutaneous (SC)
      • Others
    • By Manufacturing Type Analysis 2013 – 2018 and Forecast 2019 – 2023 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
      • In-House
      • Outsource
    • By Distribution Channel Analysis 2013 – 2018 and Forecast 2019 – 2023 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
    • By Presentation Type Analysis 2013 – 2018 and Forecast 2019 – 2023 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
      • Ampules
      • Vials
      • Prefilled Syringes
      • Lyophilized Products
      • Dry Powder Injectable
      • Pen Injectors
    • By End User Analysis 2013 – 2018 and Forecast 2019 – 2023 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
      • Human
      • Veterinary
    • Country Analysis 2013 – 2018 and Forecast 2019 – 2023 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
      • Germany
      • UK
      • France
      • Spain
      • Italy
      • Russia
      • Poland
      • Rest of Europe
    • Europe Generic Injectables Market – By Molecule Type, Drug Type, By Indication, By Route of Administration, Manufacturing Type, By Distribution Channel, By Presentation Type, By End User, and Country, 2019 – 2023
    • Europe Generic Injectables Market Dynamics – Trends
  4. Asia-Pacific Generic Injectables Market Analysis, 2013 – 2018 and Forecast, 2019 – 2023 (Revenue, USD Mn)
    • Molecule Type Analysis 2013 – 2018 and Forecast 2019 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
      • Large Molecule
      • Small Molecule
    • Drug Type Analysis 2013 – 2018 and Forecast 2019 – 2023 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
      • Monoclonal Antibodies
      • Peptide Hormones
      • Immunoglobulin
      • Cytokines
      • Blood Factors
      • Peptide Antibiotics
      • Insulin
      • Vaccines
      • Others
    • By Indication Analysis 2013 – 2018 and Forecast 2019 – 2023 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
      • Cancer
      • Diabetes
      • Cardiovascular Diseases
      • Musculoskeletal
      • CNS
      • Infections
      • Ophthalmic
      • Others
    • By Route of Administration Analysis 2013 – 2018 and Forecast 2019 – 2023 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
      • Intravenous (IV)
      • Intramuscular (IM)
      • Subcutaneous (SC)
      • Others
    • By Manufacturing Type Analysis 2013 – 2018 and Forecast 2019 – 2023 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
      • In-House
      • Outsource
    • By Distribution Channel Analysis 2013 – 2018 and Forecast 2019 – 2023 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
    • By Presentation Type Analysis 2013 – 2018 and Forecast 2019 – 2023 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
      • Ampules
      • Vials
      • Prefilled Syringes
      • Lyophilized Products
      • Dry Powder Injectable
      • Pen Injectors
    • By End User Analysis 2013 – 2018 and Forecast 2019 – 2023 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
      • Human
      • Veterinary
    • Country Analysis 2013 – 2018 and Forecast 2019 – 2023 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
      • Japan
      • China
      • India
      • ASEAN
      • Australia & New Zealand
      • Rest of Asia-Pacific
    • Asia-Pacific Generic Injectables Market – Opportunity Analysis Index, By Molecule Type, Drug Type, By Indication, By Route of Administration, Manufacturing Type, By Distribution Channel, By Presentation Type, By End User, and Country, 2019 – 2023
    • Asia-Pacific Generic Injectables Market Dynamics – Trends
  5. Latin America Generic Injectables Market Analysis, 2013 – 2018 and Forecast, 2019 – 2023 (Revenue, USD Mn)
    • Molecule Type Analysis 2013 – 2018 and Forecast 2019 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
      • Large Molecule
      • Small Molecule
    • Drug Type Analysis 2013 – 2018 and Forecast 2019 – 2023 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
      • Monoclonal Antibodies
      • Peptide Hormones
      • Immunoglobulin
      • Cytokines
      • Blood Factors
      • Peptide Antibiotics
      • Insulin
      • Vaccines
      • Others
    • By Indication Analysis 2013 – 2018 and Forecast 2019 – 2023 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
      • Cancer
      • Diabetes
      • Cardiovascular Diseases
      • Musculoskeletal
      • CNS
      • Infections
      • Ophthalmic
      • Others
    • By Route of Administration Analysis 2013 – 2018 and Forecast 2019 – 2023 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
      • Intravenous (IV)
      • Intramuscular (IM)
      • Subcutaneous (SC)
      • Others
    • By Manufacturing Type Analysis 2013 – 2018 and Forecast 2019 – 2023 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
      • In-House
      • Outsource
    • By Distribution Channel Analysis 2013 – 2018 and Forecast 2019 – 2023 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
    • By Presentation Type Analysis 2013 – 2018 and Forecast 2019 – 2023 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
      • Ampules
      • Vials
      • Prefilled Syringes
      • Lyophilized Products
      • Dry Powder Injectable
      • Pen Injectors
    • By End User Analysis 2013 – 2018 and Forecast 2019 – 2023 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
      • Human
      • Veterinary
    • Country Analysis 2013 – 2018 and Forecast 2019 – 2023 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
      • Brazil
      • Mexico
      • Argentina
      • Rest of Latin America
    • Latin America Generic Injectables Market – Opportunity Analysis Index, By Molecule Type, Drug Type, By Indication, By Route of Administration, Manufacturing Type, By Distribution Channel, By Presentation Type, By End User, and Country, 2019 – 2023
    • Latin America Generic Injectables Market Dynamics – Trends
  6. Middle East and Africa Generic Injectables Market Analysis, 2013 – 2018 and Forecast, 2019 – 2023 (Revenue, USD Mn)
    • Molecule Type Analysis 2013 – 2018 and Forecast 2019 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
      • Large Molecule
      • Small Molecule
    • Drug Type Analysis 2013 – 2018 and Forecast 2019 – 2023 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
      • Monoclonal Antibodies
      • Peptide Hormones
      • Immunoglobulin
      • Cytokines
      • Blood Factors
      • Peptide Antibiotics
      • Insulin
      • Vaccines
      • Others
    • By Indication Analysis 2013 – 2018 and Forecast 2019 – 2023 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
      • Cancer
      • Diabetes
      • Cardiovascular Diseases
      • Musculoskeletal
      • CNS
      • Infections
      • Ophthalmic
      • Others
    • By Route of Administration Analysis 2013 – 2018 and Forecast 2019 – 2023 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
      • Intravenous (IV)
      • Intramuscular (IM)
      • Subcutaneous (SC)
      • Others
    • By Manufacturing Type Analysis 2013 – 2018 and Forecast 2019 – 2023 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
      • In-House
      • Outsource
    • By Distribution Channel Analysis 2013 – 2018 and Forecast 2019 – 2023 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
    • By Presentation Type Analysis 2013 – 2018 and Forecast 2019 – 2023 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
      • Ampules
      • Vials
      • Prefilled Syringes
      • Lyophilized Products
      • Dry Powder Injectable
      • Pen Injectors
    • By End User Analysis 2013 – 2018 and Forecast 2019 – 2023 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
      • Human
      • Veterinary
    • Country Analysis 2013 – 2018 and Forecast 2019 – 2023 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
      • Gulf Cooperation Council (GCC) Countries
      • Israel
      • South Africa
      • Rest of MEA
    • MEA Generic Injectables Market – Opportunity Analysis Index, By Molecule Type, Drug Type, By Indication, By Route of Administration, Manufacturing Type, By Distribution Channel, By Presentation Type, By End User, and Country, 2019 – 2023
    • MEA Generic Injectables Market Dynamics – Trends
  7. Competition Landscape
    • Strategic Dashboard of Top Market Players
    • Company Profiles (Introduction, Financial Analysis, Product Type & Service Offerings, Key Developments, Strategies, and SWOT Analysis)
      • Novartis
      • AbbVie Inc.
      • Amgen, Inc.
      • AstraZeneca Plc
      • Baxter International Inc.
      • Gilead Sciences, Inc.
      • GlaxoSmithKline plc.
      • Johnson & Johnson
      • Merck & Co., Inc.
      • Novo Nordisk
      • Pfizer Inc
      • Hoffmann-La Roche Ltd
      • Sanofi SA
  1. Research Methodology
  2. Key Assumptions and Acronyms

Report

Company Profile

  • AstraZeneca
  • Baxter International, Inc.
  • Biocon
  • Fresenius SE & Co. KGaA
  • GlaxoSmithKline plc
  • Hikma Pharmaceuticals plc
  • Johnson & Johnson Services, Inc.
  • Lupin Ltd.
  • Merck KGaA
  • Mylan N.V.
  • Novartis AG (Sandoz International GmbH)
  • Pfizer, Inc.

Description

The Generic Injectables market is valued at USD 20.0 billion in 2021 and is poised to grow at a significant CAGR of 11.0% over 2022–2028. Generic injectables are bioequivalent to their branded counterparts; they are as safe and effective as innovator compounds. Only after the patent on the branded drug has expired can these medications be created for commercial use. Generic injectables have low R&D costs because the drug molecules are equivalent in branded and generic formulations. Drugmakers can sell generic injectables at low prices because of the minimal upfront R&D costs. According to the USFDA, a single generic competitor can result in price reductions of 30%, whereas five generic competitors can result in price reductions of 85%. Furthermore, generic drugs are approved faster than branded medicines. According to the US Food and Drug Administration (USFDA), 107 first-generation generic pharmaceuticals and 110 complicated generic drugs were approved in 2019, accounting for 11% of all generic drug product approvals. One thousand fourteen generic medicine applications were granted or tentatively approved by the generic drug program in 2019. Furthermore, the development of a new chemical entity takes roughly a decade on average, whereas generic injectables are developed in a fraction of that time. As a result, one of the primary drivers encouraging new companies to enter the market and driving the generic injectables market is the lower cost associated with generic injectables. Manufacturers in the generic injectables market are preparing for the future by keeping adequate supply chains to avoid any COVID-19-like vulnerabilities. Drug companies such as Zydus Cadila have been seen lowering the price of Remdac, the generic version of Remdesivir. Companies are utilizing government programs and financing schemes given by the BFSI industry to streamline their operations in response to turbulent market conditions. Furthermore, branded injectables’ patents are set to expire in the coming years in several countries, presenting a lucrative opportunity for generic injectables manufacturers. Generational injectables businesses target regulated markets and explore other markets to generate funds and build steady revenue streams.

Recent Market Developments:

In January 2022, Hikma Pharmaceuticals launched Hikma 503B, a new outsourced sterile compounding business. The unit would focus on providing high-quality, ready-to-administer injectables and customized medications for the US market.

In April 2022, Hospira, Inc., the world leader in generic injectable pharmaceuticals, acquired the generic injectable pharmaceuticals business of Orchid Chemicals & Pharmaceuticals Ltd., a leading Indian pharmaceuticals company, for approximately $400 Billion.

ASIA PACIFIC OFFICE

Precision Business Insights, 5th Floor, Mohan’s Elite, Opp : Bharat Petroleum Pump, Khanamet Road, Hitech City, Hyderabad – 500084

EUROPE OFFICE

Precision Business Insights, Kemp House, 152 – 160 City Road, London EC1V 2NX